Holen Sie sich die Stockscreener-App
3.02
3.21%
-0.10
Handel nachbörslich:
3.03
0.010
+0.33%
Schlusskurs vom Vortag:
$3.12
Offen:
$3.11
24-Stunden-Volumen:
4.05M
Relative Volume:
0.88
Marktkapitalisierung:
$800.74M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-10.79
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-3.51%
1M Leistung:
-19.68%
6M Leistung:
+67.78%
1J Leistung:
+116.49%
1-Tages-Spanne:
$3.01
$3.14
1-Wochen-Bereich:
$3.01
$3.22
52-Wochen-Spanne:
$1.24
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.02 | 824.60M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Does Akebia Therapeutics Inc. have pricing powerWeekly Stock Analysis & Verified Swing Trading Watchlist - khodrobank.com
Strategies to average down on Akebia Therapeutics Inc.2025 Market Outlook & Intraday High Probability Setup Alerts - Newser
Will Akebia Therapeutics Inc. outperform the marketJuly 2025 Setups & Step-by-Step Trade Execution Guides - Newser
Using Python tools to backtest Akebia Therapeutics Inc. strategiesBond Market & Real-Time Stock Entry Alerts - Newser
Regression analysis insights on Akebia Therapeutics Inc. performanceTrade Analysis Report & Long-Term Safe Investment Plans - Newser
Understanding Akebia Therapeutics Inc.’s price movementRecession Risk & High Return Stock Watch Alerts - Newser
Akebia Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
95,100 Shares at $3.14: Akebia Therapeutics Grants Inducement Stock Options to Key New Hires - Stock Titan
Stock Report: Can Akebia Therapeutics Inc. stock outperform in a bear market2025 Earnings Surprises & Accurate Buy Signal Notifications - khodrobank.com
Does Akebia Therapeutics Inc. have declining or rising EPSJuly 2025 Price Swings & Verified Momentum Stock Ideas - khodrobank.com
Analyzing drawdowns of Akebia Therapeutics Inc. with statistical toolsJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - Newser
Measuring Akebia Therapeutics Inc.’s beta against major indicesTreasury Yields & Long-Term Growth Plans - Newser
Can Akebia Therapeutics Inc. stock outperform in a bear marketMarket Growth Review & High Win Rate Trade Tips - khodrobank.com
What is Akebia Therapeutics Inc. s 5 year growth outlookEarnings Growth Report & Weekly Setup with ROI Potential - خودرو بانک
Akebia Therapeutics Inc. Stock Recovery Path — Analyst Breakdown2025 Momentum Check & Stock Market Timing Techniques - beatles.ru
Is Akebia Therapeutics Inc. reversing from oversold territoryJuly 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - Newser
Is Akebia Therapeutics Inc. forming a bottoming baseJuly 2025 Weekly Recap & Reliable Volume Spike Trade Alerts - Newser
How moving averages guide Akebia Therapeutics Inc. tradingMarket Trend Summary & Reliable Momentum Entry Alerts - Newser
Visual trend scoring systems applied to Akebia Therapeutics Inc.Market Trend Review & Free Reliable Trade Execution Plans - Newser
Using Bollinger Bands to evaluate Akebia Therapeutics Inc.2025 Technical Overview & Weekly High Return Stock Forecasts - Newser
Using Ichimoku Cloud for Akebia Therapeutics Inc. technicalsMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Why Akebia Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Breakouts & High Conviction Trade Alerts - Newser
What Fibonacci levels say about Akebia Therapeutics Inc. reboundJuly 2025 Sector Moves & Safe Swing Trade Setups - Newser
How to interpret RSI for Akebia Therapeutics Inc. stockEarnings Trend Report & Verified Entry Point Signals - Newser
Elliott Wave Theory Predicts Pullback in Akebia Therapeutics Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
Sentiment analysis tools applied to Akebia Therapeutics Inc.Market Growth Summary & AI Driven Stock Price Forecasts - Newser
Earnings Chart Overlay Points to Akebia Therapeutics Inc. UpsideJuly 2025 Trade Ideas & Reliable Price Action Trade Plans - beatles.ru
Biotech Movers: Akebia Shares Down After Pricing Stock Offering - TheStreet
What’s the recovery path for long term holders of Akebia Therapeutics Inc.Volume Spike & Safe Capital Growth Tips - Newser
Price momentum metrics for Akebia Therapeutics Inc. explainedPortfolio Gains Summary & Expert Curated Trade Setups - Newser
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.60%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):